Charles Schwab’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Charles Schwab’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-74,869	Closed	-$7.3M	–	3196
2015 Q1	$7.3M	Buy	74,869 +16,952	+29%	+$1.79M	0.01%	1233
2014 Q4	$5.38M	Buy	57,917 +250	+0.4%	+$19.7K	0.01%	1393
2014 Q3	$3.97M	Buy	57,667 +2,796	+5%	+$200K	0.01%	1562
2014 Q2	$5.75M	Buy	54,871 +1,820	+3%	+$155K	0.01%	1281
2014 Q1	$4.4M	Buy	53,051 +626	+1%	+$57.9K	0.01%	1434
2013 Q4	$3.39M	Buy	52,425 +6,846	+15%	+$406K	0.01%	1566
2013 Q3	$2.96M	Buy	45,579 +8,409	+23%	+$414K	0.01%	1583
2013 Q2	$1.59M	Buy	+37,170	New	+$1.69M	﹤0.01%	1899

Charles Schwab's GEVA Position: Q2 2015 in Review

Charles Schwab sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 74,869 shares — an estimated $7.3M sold.

Charles Schwab first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $7.3M in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

Charles Schwab reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
Charles Schwab sold 74,869 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $7.3M.
Charles Schwab first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
Charles Schwab's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $7.3M in Q1 2015.
0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Charles Schwab's 13F filing for Q2 2015, filed 14 Aug 2015.